We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Rutherrin® technology is patent pending in the United States, the European Union, Brazil, Russia, India and China. These countries account for approximately 65% of the world’s Gross Domestic Product (“GDP“) (2015 statistics). If patents are allowed to issue in these countries, the Rutherrin® technology will be able to be fully commercialized and protected in these major medical markets.
From the original on US patent .
Seems like the China and US trade deal will eliminate or address it .
Another one of the key essentials in DD here is the facts around Photofrin and even Radachlorin and how they relate back to TLT .
Photofrin got FDA approval in the 90's the lead investigator on the Canadian trials is running the Canadian trials for TLT . He says all problems with Photofrin have been corrected and improved on by TLT .
Radachlorin actually worked well had approval but had to be applied through the blood stream and so never caught on as a treatment , side effects with these early generations were a problem .
TLT has a lock on this Photo Dynamic Treatment treatment and it has proven to work .
There are maybe another 4 to 5 key DD facts to consider .